Alimera Sciences Announces Positive Outcome Of Repeat-Use Procedure For Iluvien

June 30, 2014 12:00 PM

5 0

Alimera Sciences Inc. (ALIM: Quote) announced the positive outcome of the Repeat-Use Procedure for Iluvien for the treatment of chronic diabetic macular edema or DME in an additional 10 European Union countries.

Alimera said it submitted the application through the Mutual Recognition Procedure or MRP with the Medicines and Healthcare products Regulatory Agency of the United Kingdom (MHRA) serving as the Reference Member State.

Read more

To category page

Loading...